Velcade hits barricade in EU approval for relapsed NHL
This article was originally published in Scrip
Executive Summary
Janssen-Cilag (Johnson & Johnson) has withdrawn its supplemental EU filing for Velcade (bortezomib) in non-Hodgkin's lymphoma after the EMA's advisory group, the CHMP, indicated that the data in the application do not support approval.